ArticleIranian journal of pharmaceutical research : IJPR
Combined Omega-3 Fatty Acid and Folic Acid Supplementation Reduces Neonatal Hypoxic-Ischemic Brain Injury via Anti-inflammatory and Anti-apoptotic Mechanisms.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From oxidative stress to epigenetic regulation: Molecular mechanisms of preterm brain injury and neuroprotective strategies (Review).Molecular medicine reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neonatal hypoxic ischemia (HI) injury results in neuronal cell death, which remains clinically challenging to mitigate. Omega-3 polyunsaturated fatty acids (PUFAs) are known for their antioxidative and anti-inflammatory effects. Folic acid (FA) correlates with apoptosis in neural stem cells and neurons. Objectives: This study aimed to evaluate whether combined PUFA and FA supplementation mitigates neonatal HI brain injury by reducing apoptosis, inflammation, neurotransmitter imbalance, and electrophysiological dysfunction, thereby offering enhanced neuroprotection and functional recovery. Methods: Brain tissue damage, orthodromic population spike (OPS), and hypoxic injury potential (HIP) were measured. Amino acid neurotransmitter concentration in the hippocampus sections was measured. Markers of inflammation and apoptosis were assayed from HI-induced rat brains and lipopolysaccharide (LPS)-induced microglia BV-2 cells. Results: The HI caused severe damage to brain tissues that were potentially prevented by PUFA-FA by reducing the infarct size by 88%. The PUFA-FA treatment decreased the latency time (51 and 43 s) and increased swimming velocity (152 and 170 mm/s) on training days 3 and 5. The PUFA-FA showed an improved OPS decay time of 327 s, OPS recovery rate (62 s), and recovery amplitude (58 s). Whereas it caused an average 57% HIP incidence with a notably delayed onset (564 s) and duration (182 s). The PUFA-FA treatment also decreased the HI-induced release of amino acid neurotransmitters (Asp, Glu, and Gly) and GABA. The PUFA-FA suppressed the levels of proinflammatory cytokines and chemokines (iNOS, COX-2, TNF-α, IL-1β, and IL-6) and might mediate the inhibition of the NF-κB signaling pathway. The PUFA-FA reduced apoptosis as evidenced by lowered expression of AIF, caspase-3, and PARP genes. Conclusions: The PUFA and FA reduced HI-induced brain infarct size, with the combination showing greater protection compared to individual effects. Both improved cognitive performances, decreasing latency times and enhancing swimming velocity. The PUFA-FA supplementation synergistically restored memory, learning, and motor functions, highlighting strong neuroprotective effects against HI-induced neuronal degeneration and cognitive impairments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.